Positive results demonstrate promising new option for women seeking better, personalized treatment
GRENOBLE, France & MINNEAPOLIS, Minnesota (Feb. 14, 2024) – UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI. This milestone indicates a new era for millions of women suffering from SUI, and signals an exciting transition for surgeons treating SUI not only in France, where the female patient was treated, but also across Europe and the U.S. It also follows closely on the heels of the successful results of the complete treatment cohort of the first-in-man clinical feasibility study. Results of this clinical study will contribute to the design and implementation of UroMems’ pivotal clinical trial in Europe and the U.S.
Successful primary and secondary results demonstrate proof of feasibility in male patients, paving way for launch of large-scale pivotal clinical study in the U.S. and Europe
GRENOBLE, France & MINNEAPOLIS, Minnesota (December 13, 2023) – UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today it has reached a significant milestone: the complete treatment cohort in the first-of-its-kind clinical feasibility study has successfully reached the six-month primary endpoints.
Funds will support pivotal clinical study in U.S. and Europe
GRENOBLE, France & MINNEAPOLIS, Minnesota (November 13, 2023) – UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), is delighted to announce it will receive a financial award from the European Innovation Council Accelerator program. The funding will go toward pivotal SUI trials for the UroActive™ System treating women and men in the U.S. and Europe.
Initial clinical trial results will inform pivotal clinical study in U.S. and Europe
GRENOBLE, France & MINNEAPOLIS, Minnesota (September 12, 2023) – UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed enrollment in its first-in-man study of the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI. The results of this initial clinical study will support design and implementation of UroMems’ pivotal SUI trial in Europe and the U.S.
Initial clinical study results will inform pivotal clinical trial in U.S. and Europe
GRENOBLE, France & MINNEAPOLIS, Minnesota (July 20, 2023) – UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-ever implant of the UroActive™ smart, automated artificial urinary sphincter (AUS) in a female patient. This milestone indicates a new era for millions of women suffering from SUI, and results of this clinical study will contribute to the design and implementation of UroMems’ pivotal clinical trial in Europe and the U.S.
Initial clinical trial results will inform pivotal clinical study in U.S. and Europe
GRENOBLE, France & MINNEAPOLIS, Minnesota (June 6, 2023) – UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully met the primary endpoints for the initial male patient in its SOPHIA study. SOPHIA is the first-in-man study of the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI. The results of this clinical study will support design and implementation of UroMems’ pivotal clinical trial in Europe and the U.S.
STeP inclusion reflects the potential improvements in safety of its UroActive™ System
Grenoble, France & Minneapolis, Minnesota (April 20, 2023) – UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that they have received Safer Technologies Program (STeP) designation from the U.S. Food and Drug Administration (FDA) for UroActive Smart Continence Therapy. STeP is a collaborative program intended to help reduce the time it takes to develop and obtain marketing authorization for eligible devices.
This initial clinical trial is a key milestone in the development of its UroActive™ System
Grenoble, France (November 29, 2022) – UroMems, a global company developing breakthrough, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-in-human implant of the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) investigational device to treat SUI. This initial clinical study is a key milestone in the development of UroActive.
GRENOBLE, France, May 11, 2022 (GLOBE NEWSWIRE) -- UroMems, developer and manufacturer of UroActive™, the first active medical implantable device for treating stress urinary incontinence, today announced the elevation of Steffen Hovard, currently on UroMems’ Board, to Chairman of the Company’s Board of Directors. Mr. Hovard is a medical device industry leader in the U.S, with a successful track record in urology. As chairman, he will be focused on increasing UroMems’ financial, clinical development and commercial footprint in the U.S.
GRENOBLE, France, April 06, 2021 (GLOBE NEWSWIRE) -- UroMems, developer and manufacturer of the electronic artificial urinary sphincter (eAUS), today announced that it has raised an additional €7 million in a second tranche of its previously announced Series B financing round completed in May 2020. The additional capital was provided by existing investors including Hil-Invent GmbH, Financière Arbevel, Wellington Partners, Bpifrance, via its FABS fund, Supernova Invest and btov Partners, and brings the total raised in this round to €23 million. Further participation from existing investors raised additional €7 million.